PepGen Inc. (NASDAQ:PEPG) Short Interest Update

PepGen Inc. (NASDAQ:PEPG) was the target of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 2,810,000 shares, an increase of 229.6% from the February 13th total of 852,600 shares. Based on an average trading volume of 2,690,000 shares, the short-interest ratio is presently 1.0 days. Currently, 10.3% of the company’s shares are sold short.

PepGen Stock Performance

NASDAQ:PEPG traded up $0.14 during trading hours on Friday, hitting $2.39. The stock had a trading volume of 229,186 shares, compared to its average volume of 786,015. The business’s 50 day moving average is $2.10 and its 200-day moving average is $5.26. The company has a market cap of $78.13 million, a price-to-earnings ratio of -0.80 and a beta of 0.96. PepGen has a one year low of $1.16 and a one year high of $19.30.

PepGen (NASDAQ:PEPG) last posted its earnings results on Monday, February 24th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.13. On average, sell-side analysts anticipate that PepGen will post -2.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PEPG has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of PepGen in a research report on Monday, February 24th. Bank of America lowered shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price for the company. in a report on Monday, December 16th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of PEPG. China Universal Asset Management Co. Ltd. bought a new stake in PepGen in the 4th quarter valued at $26,000. Corton Capital Inc. acquired a new position in shares of PepGen during the fourth quarter worth about $68,000. XTX Topco Ltd bought a new position in shares of PepGen during the third quarter worth about $130,000. Deutsche Bank AG raised its position in PepGen by 442.5% in the 4th quarter. Deutsche Bank AG now owns 44,735 shares of the company’s stock valued at $170,000 after buying an additional 36,489 shares during the last quarter. Finally, Barclays PLC grew its stake in shares of PepGen by 318.7% during the 3rd quarter. Barclays PLC now owns 21,971 shares of the company’s stock worth $189,000 after acquiring an additional 16,723 shares in the last quarter. Institutional investors own 58.01% of the company’s stock.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.